Biomarkers in chronic pelvic pain syndrome: did we find the Holy Grail? by Kessler, Thomas M
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Biomarkers in chronic pelvic pain syndrome: did we find the Holy Grail?
Kessler, Thomas M
DOI: https://doi.org/10.1111/bju.13922
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-138081
Originally published at:
Kessler, Thomas M (2017). Biomarkers in chronic pelvic pain syndrome: did we find the Holy Grail?
BJU International, 120(1):1.
DOI: https://doi.org/10.1111/bju.13922
Biomarkers in chronic pelvic pain syndrome: did
we ﬁnd the Holy Grail?
The legend of the Holy Grail has fascinated people since theMiddle Ages and is one of the most enduring in literature andart, from Chretien de Troyes’ Li Contes del Graal, Robert de
Boron’s Joseph d’ Arimathie, Wolfram von Eschenbach’s Parzifal, Sir
Thomas Malory’s Le Morte Darthur, Richard Wagner’s Parsifal, Monty
Python and the Holy Grail, Steven Spielberg’s Indiana Jones and the
Last Crusade, Terry Gilliam’s The Fisher King, and Dan Brown’s The
Da Vinci Code. The Grail is most commonly identiﬁed as the cup used
by Christ at the Last Supper and it is believed to have miraculous
powers. The search for the Holy Grail symbolises a human longing for
something we very much strive for but hardly achieve – such as
elucidating underlying patho-mechanisms of chronic pain
syndromes. . .
Chronic pelvic pain syndrome (CPPS) is one of the major challenges in
urology. It is characterised by pain perceived in structures related to
the pelvis for at least 6 months without conﬁrmed infection or other
obvious local pathology [1]. Although CPPS is highly prevalent, affects
the lives of millions of people worldwide, and also imposes a
substantial economic burden on every healthcare system, the cause of
this syndrome is still unknown and available treatments often fail. An
individualised, patient-tailored bio-psycho-social approach engaging the
patient in a collaborative journey towards self-management is strongly
recommended [1–4] (Fig. 1).
For the development of new therapies, we have to improve the
understanding of the underlying causes of CPPS. In 2008, the National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the
National Institutes of Health (NIH) established the Multidisciplinary
Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network
(www.mappnetwork.org), as a comprehensive whole-body initiative
including research with clinical, epidemiological, and basic science
expertise. The contribution of this research network to our current
knowledge in the CPPS ﬁeld is tremendous, mirrored by an impressive list
of MAPP publications. In this month’s issue of the BJUI, Dagher et al. [5]
present the ﬁndings from the MAPP Research Network on biomarkers,
which have been identiﬁed considering basic biochemistry and physiology
of CPPS as a function of inﬂammation, dysregulation of extracellular
matrix turnover, and vascular dysfunction: matrix metalloproteinase
(MMP)-2, MMP-9, MMP-9/neutrophil gelatinase-associated lipocalin
(NGAL) complex, NGAL, vascular endothelial growth factor (VEGF),
VEGF receptor 1 (VEGF-R1). Although this study provides new insights
into the pathophysiology, as several of these biomarkers were associated
with the clinical symptoms of CPPS, no biomarker could usefully
discriminate patients with CPPS from controls. It may be hypothesised that
focusing on central aspects [4] instead of end organ abnormalities may be
more appropriate. Indeed, neuro-imaging studies found cerebral correlates
for CPPS, for instance, regional white matter abnormalities characterise
CPPS and can distinguish between visceral diagnoses [6].
Nevertheless, although biomarkers, characterised as unique substances
or features found in people with speciﬁc conditions that serve to
identify the presence of a disorder, are promising, more research is
urgently needed. CPPS is still a mystery! We have not yet found the
Holy Grail, which may be covered by the glaciers’ eternal ice - up to
the Swiss Alps. . .
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